Laboratory Tests for Geodon (Ziprasidone)
Before starting ziprasidone, obtain baseline serum potassium and magnesium levels in all patients at risk for electrolyte disturbances, and obtain a baseline ECG to assess QTc interval 1.
Required Baseline Testing
Electrolyte Panel
- Serum potassium and magnesium measurements are mandatory for patients at risk of significant electrolyte disturbances 1
- Any hypokalemia or hypomagnesemia must be corrected before initiating ziprasidone therapy
- Patients at particular risk include those on diuretics, with eating disorders, chronic diarrhea, or malnutrition
Baseline ECG
The FDA label explicitly addresses ECG monitoring in the context of QTc prolongation risk 1. While the label specifically mandates electrolyte monitoring, ECG monitoring is strongly recommended given that:
- Ziprasidone causes dose-dependent QTc prolongation (mean increases of 4.5-19.5 ms at therapeutic doses) 2
- The drug should be discontinued if QTc measurements persistently exceed 500 ms 1
- Clinical pharmacology studies demonstrate QTc increases of approximately 6 ms for each 100 ng/mL increase in ziprasidone concentration 2
The European Heart Journal guideline on psychotropic medication-induced arrhythmia supports baseline ECG monitoring for medications with QT-prolonging effects 3, though ziprasidone is not specifically mentioned in the provided excerpt.
Ongoing Monitoring
Patients started on diuretics during ziprasidone therapy require periodic monitoring of serum potassium and magnesium 1.
Clinical Context and Caveats
Risk Stratification
Research demonstrates that QTc prolongation ≥60 ms occurred in less than 1% of patients in clinical trials, and only one subject reached QTc ≥480 ms among 4,306 adults studied 2. However, case reports document significant QTc prolongation even with single low doses (20 mg IM) 4, emphasizing individual variability.
Baseline QTc Considerations
Analysis of clinical trial data shows that QTc prolongation ≥60 ms occurred exclusively in subjects with baseline QTc ≤400 ms 2. This suggests patients with already-prolonged QTc at baseline may have different risk profiles.
Pediatric Populations
In children and adolescents, one study found mean QTc prolongation of 28 ms with low doses (≤40 mg/day), with three subjects reaching QTc ≥450 ms 5. Close ECG monitoring is particularly warranted in pediatric patients 6, 5.
Common Pitfall
Automated ECG readings may not reliably identify prolonged QTc intervals. One study found poor agreement (kappa = 0.25) between automated and manual QTc measurements 5. Manual verification of QTc intervals is recommended, particularly when automated readings approach or exceed 440 ms.
Contraindications
Ziprasidone is contraindicated in patients with known QT prolongation, recent myocardial infarction, uncompensated heart failure, or concurrent use of other QTc-prolonging medications 1.